Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kathryn Harrison

Physician Assistant Englewood, CO Physician Assistant

NPI 1316299126 CMS profile 10574741

3701 S Clarkson St Ste 400, Englewood, CO 80113

Open in the dashboard

General payments

$11,720

528 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathryn Harrison of Englewood, CO is reported in the CMS Open Payments database as having received $11,720 across 528 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,633 147
2024 General $3,083 154
2023 General $2,214 102
2022 General $1,550 68
2021 General $1,239 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Harrison
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kathryn Harrison were reported at $3,633. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kathryn Harrison Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,239 $132 $37–$438 $132
2022 $1,550 $155 $48–$522 $149
2023 $2,214 $167 $52–$557 $160
2024 $3,083 $178 $55–$600 $164
2025 $3,633 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,090 114 payments
  2. Galderma Laboratories, L.P. $1,152 89 payments
  3. Sun Pharmaceutical Industries Inc. $1,137 41 payments
  4. Genzyme Corporation $954 33 payments
  5. Novartis Pharmaceuticals Corporation $900 39 payments
  6. Arcutis Biotherapeutics, Inc. $620 26 payments
  7. Journey Medical Corporation $526 2 payments
  8. Amgen Inc. $480 16 payments
  9. UCB, Inc. $470 18 payments
  10. Regeneron Healthcare Solutions, Inc. $430 15 payments
  11. Other $2,961 135 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,388 517 payments
  2. Education $831 10 payments
  3. Consulting Fee $500 1 payment
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,299 42 payments
  2. RINVOQ $778 30 payments
  3. SKYRIZI $731 28 payments
  4. COSENTYX $566 25 payments
  5. Zoryve $552 22 payments
  6. Otezla $480 16 payments
  7. ILUMYA $466 25 payments
  8. AKLIEF $400 29 payments
  9. TREMFYA $372 10 payments
  10. SOTYKTU $365 15 payments
  11. Other $5,341 287 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

920

Median for Physician Assistant: 241

Drug cost

$532,740

Median for Physician Assistant: $4,110

Branded share of claims

14.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 67 $275,265
Taltz Autoinjector Ixekizumab Brand 13 $103,561
Otezla Apremilast Brand 16 $81,816
Opzelura Ruxolitinib Phosphate Brand 11 $21,418
Vtama Tapinarof Brand 11 $14,710
Pimecrolimus Generic 23 $7,416
Fluorouracil Generic 74 $6,144
Clobetasol Propionate Generic 89 $4,073
Tacrolimus Generic 19 $3,488
Doxycycline Hyclate Generic 38 $2,090

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$129,284

Of which drugs: $7,213

Medicare patients

561

Average age 73

Services billed

7,077

324 women, 237 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Arthritis 45%
Ischemic heart disease 20%
Depression 20%
Osteoporosis 18%
Chronic kidney disease 15%
Cancer 15%
Diabetes 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 12 3,800 $5,084
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 134 $103

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $367
  • Regeneron Healthcare Solutions, Inc. $190
$557 67 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $247
$247 — —
SKYRIZI
  • AbbVie, Inc. $197
$197 — —
RINVOQ
  • AbbVie, Inc. $173
$173 — —
DYSPORT
  • Galderma Laboratories, L.P. $160
$160 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

528 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record